Palvella Therapeutics initiated with a Buy at Truist

Truist analyst Danielle Brill initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $56 price target Palvella is in a sweet spot for biotech investment with QTORIN, a de-risked potential pipeline in a product with clean proof-of-concept data in microcystic lymphatic malformations, a rare genetic skin disease, a registrational trial that has been optimized to replicate Phase 2 findings, and a potential blockbuster opportunity with no marketed competition, the analyst tells investors in a research note. The firm sees a value inflection approaching in the next 5-9 months.